Amendments to the Claims

Please amend claims 1, 8-9 and 18 as indicated in the listing of claims.

The listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (Currently amended) A method of treating a pathology in a mammal, said pathology being ~~selected from the group consisting of~~ synovitis or subchondral bone edema, ~~and cartilage degradation~~, wherein said treatment ~~further~~ comprises administering to said mammal a therapeutically effective amount of an aminosugar, wherein the aminosugar is injected intra-articularly.

2. (Original) The method according to claim 1, wherein said aminosugar is selected from the group consisting of N-acetylglucosamine, glucosamine, galactosamine, N-acetylgalactosamine, iminocyclitol, and pharmaceutically acceptable salts thereof.

3. (Original) The method according to claim 1, wherein said aminosugar is entrapped in a matrix.

4. (Previously amended) The method according to claim 3, wherein said matrix is selected from the group consisting of a particle, an implant and a gel.

5. (Original) The method according to claim 4, wherein said particle comprises a liposome, a nanosphere, a microsphere, or a suspension.

6. (Previously amended) The method according to claim 4, wherein said implant comprises a polymer or a pump.

7. (Original) The method according to claim 4, wherein said gel comprises an in situ implant forming gel, a semi-solid gel, a hydrogel, or a thermo sensitive gel.

8. (Currently Amended) An injectable formulation for intra-articular treatment of a pathologies associated with ~~a joint condition~~ synovitis or subchondral bone edema comprising an aminosugar which is entrapped by a matrix, wherein said matrix comprises a particle, an implant, or a gel.

9. (Currently Amended) A method of treating pathologies associated with ~~a joint condition~~ synovitis or subchondral bone edema comprising administering a therapeutically effective amount of N-acetylglucosamine as a controlled release formulation.

10. (Original) The method according to claim 9, wherein N-acetylglucosamine is administered by intra-muscular injection or intra-articular injection.

11. (Original) The method according to claim 9, wherein N-acetylglucosamine is administered by subcutaneous injection or infusion.

12. (Canceled) The method of claim 9 wherein the pathologies associated with a joint condition is selected from the group consisting of synovitis, subchondral bone edema and cartilage degradation.

13. (Canceled) The method of claim 12 wherein the pathologies is synovitis.

14. (Canceled) The method of claim 12 wherein the pathologies is subchondral bone edema.

15. (Canceled) The method of claim 12 wherein the pathologies is cartilage degradation.

16. (Original) The method of claim 9 wherein the joint condition is not osteoarthritis.

17. (Original) The method of claim 9 wherein the joint condition is not rheumatoid arthritis.

18. (Currently Amended) A method of treating ~~a joint condition~~ synovitis or subchondral bone edema comprising the steps of:

a.diagnosing a pathological marker associated with ~~a joint condition~~ synovitis or subchondral bone edema; and

b.administering an aminosugar in a therapeutically effective formulation wherein said aminosugar is selected from the group consisting of N-acetylglucosamine, glucosamine, galactosamine, N-acetylgalactosamine, iminocyclitol, and pharmaceutically acceptable salts thereof.

19. (Canceled) The method of claim 18 wherein the pathological marker is selected from the group consisting of synovitis, subchondral bone edema and cartilage degradation.

20. (Canceled) The method of claim 19 wherein the pathological marker is synovitis.

21. (Canceled) The method of claim 19 wherein the pathological marker is subchondral bone edema.

22. (Canceled) The method of claim 19 wherein the pathological marker is cartilage degradation.

23. (Original) The method of claim 18 wherein the joint condition is not osteoarthritis.

24. (Original) The method of claim 18 wherein the joint condition is not rheumatoid arthritis.

25. (Original) The method of claim 18 wherein the step of administering an aminosugar is performed by an administration route selected from the group consisting of intra-articular, intramuscular, infusion pump or subcutaneous.

26. (Original) The method of claim 25 wherein the administration route is intra-articular.

27. (Original) The method of claim 18, wherein the aminosugar is selected from the group consisting of N-acetylglucosamine, glucosamine, galactosamine, N-acetylgalactosamine, iminocyclitol, combination therapies thereof, pharmaceutically acceptable salts thereof, and injectable formulations thereof.

28. (Original) The method of claim 27 wherein the aminosugar is N-acetylglucosamine.

29. (Original) The method of claim 27 wherein the injectable formulations thereof are selected from the group consisting of matrix particle, matrix gel and controlled release formulation.

30. (Original) The method of claim 27 wherein the combination therapy thereof combined the aminosugar with a compound selected from the group consisting of anti-inflammatory drugs and hexoaminidase inhibitors.

31.-33. (Canceled)